Shire to announce third quarter 2018 results
Shire to announce third quarter 2018 results
Dublin, Ireland – October 18, 2018 – Shire plc (LSE: SHP, NASDAQ: SHPG), will announce third quarter 2018 earnings on Thursday November 1, 2018.
|
Results press release will be issued at: |
12:00 GMT / 08:00 EDT |
|
Investor conference call time: |
14:00 GMT / 10:00 EDT |
Live conference call for investors:
Flemming Ornskov, MD, M.P.H., Chief Executive Officer and Thomas Dittrich, Chief Financial Officer will host the investor and analyst conference call at 10:00 am EDT / 14:00 GMT.
The details of the conference call are as follows:
|
UK dial in: |
0800 358 9473 or +44 333 300 0804 |
|
US dial in: |
1 855 857 0686 or 1 631 913 1422 |
|
International Access Numbers: | |
|
Password/Conf ID: |
28705371 # |
|
Live Webcast: |
Replay:
A replay of the presentation will be made available, subject to approval by the UK Takeover Panel, for two weeks by phone and for three months by webcast. Replay information made available will be contained on the Investor Relations section of Shire’s website at http://investors.shire.com/.
For further information please contact:
| Investor Relations | ||
| Christoph Brackmann | [email protected] | +41 41 288 4129 |
| Sun Kim | [email protected] | +1 617 588 8175 |
| Scott Burrows | [email protected] | +41 41 288 4195 |
| Media | ||
| Katie Joyce | [email protected] | +1 781 482 2779 |
About Shire
Shire is the global biotechnology leader serving patients with rare diseases and specialized conditions. We seek to push boundaries through discovering and delivering new possibilities for patient communities who often have few or no other champions. Relentlessly on the edge of what’s next, we are serial innovators with a diverse pipeline offering fresh thinking and new hope. Serving patients and partnering with healthcare communities in over 100 countries, we strive to be part of the entire patient journey to enable earlier diagnosis, raise standards of care, accelerate access to treatment, and support patients. Our diverse portfolio of therapeutic areas includes Immunology, Hematology, Genetic Diseases, Neuroscience, Internal Medicine, and Ophthalmics.
Championing patients is our call to action - it brings the opportunity - and responsibility - to change people’s lives.